Prasinezumab

Prasinezumab ( , ; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Prasinezumab ( , ; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease. No significant effect on disease progression was seen in a 52-week phase 2 clinical trial.

In any case, the trial was extended and development of the drug continues. There have been concerns about research misconduct and data fabrication relevant to prasinezumab. As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease.

It is under development by Prothena Biosciences and Roche.

See also

Cinpanemab

Prasinezumab - AlzForum

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371817031 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.